We demonstrated that inhibition of PDE4DIP is an unexpected vulnerability of KRAS-mutant CRC cells, suggesting that PDE4DIP may be a promising target for the effective treatment of KRAS-mutant CRC clinically. The gene discussed is KRAS; the disease is colorectal carcinoma.